










* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone







Year code and study name	Months & treatment	Deaths/woman-years		Polychemo. deaths		Ratio of annual death rates Polychemo. : Control	
		Allocated polychemo.	Adjusted control	Logrank O-E	Variance of O-E		
(a) CMF regimens (including other non-anthracycline agents)							
73B INT Milan 7205	12 CMF	0/2127	0/1427				
75E2 Manchester I	12 CMF	0/434	0/436				
76C Glasgow	12 CMF	0/835	0/625				
76E EORTC 09771	24 CMF	0/1481	0/1233				
77B1+2 DanishBCG77bpre	12 CMF	0/2293	0/1741				
77G1 Vienna	36 CMFV	0/717	0/646				
78E UK/Asia Collab.	124 CMF	0/1352	0/1178				
78K3 IBCSG/Ludwig III post	12 CMF	2/1414	1/1104	0.5	0.7		
78V2 ECOG EST6177 post	12 CMFPr	0/566	0/599				
79B1 SWOG7827ApoER+	112 CMFVPr	2/2614	1/2413	0.5	0.8		
79C CaseWesternB ER+	112 CMFVPr	0/432	0/465				
79E Guy's/Manch. II	12 CMF	0/1575	0/1145				
79H Paris N-	6 CMF	-1/113	-985	(no data)			
80F INTMilan 8004 N-	12 CMF	0/589	0/358				
80J1 Vienna Gyn. post	† 6 CMF	0/194	0/223				
80L SWOG 7985	?? CMFV			(no data)			
81H EST1180/SW.8294	6 CMFPr	0/2851	0/2337				
82C DanishBCG82cpost	† 9 CMF	1/4464	0/4243	0.5	0.3		
84D NCI-C MA.4	† 6 CMF	1/1828	0/1707	0.4	0.2		
85J1+3 PetrovStPetersb'g	† 4 CMF; 2TtMF	0/1844	2/1704	-0.5	0.3		
86H2 IBCSG VII *	†3/6 CMF	0/5820	3(0/1804)				
87D3 GABG 3 Germany	† 6 CMF	-1/066	-916	(no data)			
88C NSABP B-20	†?? CMF	0/6146	0/5921				
88D IBCSG IX	† 3 CMF	2/4391	0/4149	1.0	0.5		
89A2 SITAM-01	† 6 CMF	0/287	0/277				
89E4+9 GROCTA V Italy	† 6 CMF	-2/16	-168	(no data)			
89J1 CRCRAMS Moscow	6 CMF	0/39	0/24				
89V Romagnolo Italy	6 CMF	0/800	0/781				
90P Amsterdam C8913	6 CMF	0/633	0/452				
90S1 IBCSG VIII	6 CMF			(no data)			
90X1 Tokyo CIH	6 CMF	0/611	0/634				
93S Hamburg, Germany	6 CMF	0/396	0/430				
Sweden-Finland	9 CMF			(no data)			

(a) subtotal with data § * **8/ 4/** **2.4 2.7** **2.44 (SE 0.98)**
 46733 41664
 (0.0%/y) (0.0%/y) **increase**
 2p > 0.1; NS

(b) Anthracycline regimens

74D1 DFCI 74-063 *	7/3.5 AC	0/47	2(0/17)				
76H1 West Midlands N+	6 CMFVAFol	0/1917	0/1409				
76L1 Cologne	?? AC			(no data)			
80B3+4 N Sweden BCG	† 8 AC	0/639	1/526	-0.4	0.2		
80C2 SESwed.BCGB post	6 AC	0/233	1/169	-0.6	0.2		
80S1 Helsinki	† 8 FAC	0/313	1/257				
80Z Wessex	† 6 VAP/VAC	0/452	0/391				
82F MD Anders.8227 N-	4 FACVPr	0/446	0/407				
83B GROCTA I Italy ER+	† 6 CMF; 4 IE	0/1474	0/1311				
84C NSABP B-16 post *	†24 MeIF+A/3AC	0/6964	2(0/3102)				
84Q4+5 Austrian BCSG 4	† 6 CMFVA	-7/70	-765	(no data)			
86P2+3 FASG France	† 6 FEC	0/3187	0/2986				
89@ Bari Italy N-	6 FEC	0/644	0/539				
89B1 SWOG 8814 *	† 6 FAC	4/6923	4(1/2118)	0.1	0.9		
89D IGR Paris	† 6 FAC/FEC	0/3408	0/3118				
90C6 FASG GFEA 07	† 6 FEC	0/649	0/603				
92D Amsterdam C9203	† 4 EC	0/179	0/178				
93H IBCSG 11-93 N+pre	† 4 AC	-3/307	-302	(no data)			
93M1+2 IBCSG 12-93 N+post	† 4 AC			(no data)			
94F JCOG 9401 N+post	† 6 AC	0/200	0/202				

(b) subtotal with data § * **4/ 7/** **-0.9 1.3** **0.51 (SE 0.63)**
 27675 26806
 (0.0%/y) (0.0%/y) **reduction**
 2p > 0.1; NS

(c) Other polychemotherapy

73C1 Mayo 70-56-32	12 CFPr	0/158	0/130				
74E UK MCCC 003	6 CVF/CVM	1/710	2/568	-0.6	0.7		
75G Northwick Park	12 MeIV	0/550	0/601				
76H2 West Midlands N-	6 ChiMF	0/3692	0/3578				
76K HD I W. Germany	24 ChiF	-1/451	-372	(no data)			
76P King's CRC M/M	24 MeIM	0/799	0/726				
77E Oxford	24 MeIMF	0/776	0/599				
77W2 Montpellier	12 CVF			(no data)			
78M3 NCCIG-773051post	10 CFPr	0/568	0/627				
81E NSABP B-13 N-	11 MFFol	0/3883	0/3416				
86D1 UK Multicentre	† 6 CVF/CVM	0/352	0/329				
88C NSABP B-20	†?? MFFol	2/6156	0/5921	1.0	0.5		
92B2 HE1092 Greece	†6 CMzF	0/540	0/633				
93A1245 UKCCCR ABC	† various			(no data)			

(c) subtotal with data § **3/ 2/** **0.4 1.2** **1.35 (SE 1.05)**
 18184 17128
 (0.0%/y) (0.0%/y) **increase**
 2p > 0.1; NS


Total (a + b + c) * **15/ 13/** **1.9 5.3** **1.436 (SE 0.523)**
 92592 85598
 (0.0%/y) (0.0%/y) **increase**
 2p > 0.1; NS

■ 99% or ◁▷ 95% confidence intervals

Heterogeneity between 3 subtotals: $\chi^2 = 2.2$; $p > 0.1$; NS

Heterogeneity within subtotals: $\chi^2 = 6.9$; $p > 0.1$; NS


Heterogeneity between 11 trials: $\chi^2 = 9.1$; $p > 0.1$; NS





§ 6 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 3923; allocated control: 3508)


* For balance, control patients in 3-way trials count half or twice in subtotal(s) and in final total of deaths/women.


† Chemotherapy plus tamoxifen versus same tamoxifen alone























§ 9 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 943; allocated control: 880)


* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/women.


† Chemotherapy plus tamoxifen versus same tamoxifen alone













§ 9 trials with no data do not contribute to subtotals or to the overall total (allocated polychemo.: 4501; allocated control: 3963)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone





§ 9 trials with no data do not contribute to subtotals but to the overall total (allocated polychemo.: 4501; allocated control: 3963)

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/women.

† Chemotherapy plus tamoxifen versus same tamoxifen alone

